MedPath

User Evaluation of the MiniMed 640G Insulin Pump

Not Applicable
Completed
Conditions
Type 1 Diabetes
Type 2 Diabetes
Interventions
Device: MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
Registration Number
NCT01991548
Lead Sponsor
Medtronic Diabetes
Brief Summary

This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia. The objective of the study is to evaluate subject acceptance of a new insulin pump and transmitter together with the accompanying training materials. Descriptive data from participant questionnaires and device uploads will be evaluated.

Pediatric subjects between the ages of 7 - 18 years and adults from the age of 19 years of age upwards, who currently use an insulin pump in the management of their type 1 or type 2 diabetes, will be invited to participate. Each subject will be trained on the study device and then use it for approximately four weeks. During this time there will be three in-clinic visits and four follow-up phone calls, scheduled at the subjects' convenience. At the end of this period, they will revert back to their original insulin pump and complete a questionnaire on the study pump training materials, features and usability.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Diabetic participants with study devicesMiniMed® 640G Insulin Pump and Guardian® Link Transmitter-
Primary Outcome Measures
NameTimeMethod
User Acceptance of the New MiniMed 640G Insulin Pump and Guardian Link TransmitterFour weeks of pump wear

Descriptive summary will be used to characterize the results of the study questionnaires. The questionnaire will use a Likert scale (rating of 1 to 7) to assess subject acceptance of the MiniMed 640G, Guardian Link Transmitter, and the training materials. A response of 4 or greater will be considered positive on a Likert scale for training materials and product acceptance.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

The Royal Melbourne Hospital

🇦🇺

Patkville, Australia

University College Hospital

🇬🇧

London, United Kingdom

St Vincent Hospital and The University of Melbourne

🇦🇺

Fitzroy, Australia

King's College London

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath